Aron Tendler has a total of 277 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical efficacy of accelerated vs. standard H1-coil TMS dosing: a prospective, multisite, 12-month durability study

    by M.S. Reddy, Aswin Kumar Mudunuru, Yiftach Roth, Eliza Brink, Molly Davis, Dawn DeBrocco, Shelli Ellis, Lindsey Jones, Aftab Khan, Carlene MacMillan, et al.

  • Open Access

    Case Report: Prism for PTSD in severe traumatic brain injury with psychiatric comorbidities: two cases

    by Diana Ghelber, Tal Harmelech, Aron Tendler

    Background: Traumatic brain injury (TBI) with post-traumatic stress disorder (PTSD) is treatment-resistant, with conventional psychotherapy showing limited efficacy due to neurocognitive impairments. Case Summary: We report two patients with severe TBI and psychiatric comorbidities treated with Prism neurofeedback. Case 1: 44-year-old female, 35 years post-childhood TBI, with agoraphobia and hyperacusis, achieved 42% PTSD reduction and substantial functional gains (social reintegration, independent driving) sustained through 4-month follow-up. Case 2: 40-year-old male, 3.5 years post-adult TBI with bipolar II disorder and severe PTSD (PCL-5 = 62), achieved 90% PTSD reduction with complete remission sustained at 1-month follow-up, enabling return to work and family system transformation. Both patients developed personalized regulatory strategies and maintained gains without relapse. Conclusions: Prism neurofeedback demonstrates clinically meaningful outcomes in severe TBI-PTSD where traditional psychotherapy shows limited efficacy. The intervention’s circumvention of cognitive processing demands may explain the favorable outcomes. Controlled trials are warranted.

  • Open Access

    Real-Time EEG-Derived Amygdala Neurofeedback for Post-Traumatic Stress Disorder: A Clinical Case Series

    by Diana Ghelber, Tal Harmelech, Aron Tendler

    Background: Post-traumatic stress disorder (PTSD) affects millions globally, with 40–50% of patients not responding adequately to first-line treatments. Prism neurofeedback, an FDA-cleared electroencephalography (EEG)-based system targeting amygdala-derived biomarkers, has demonstrated efficacy in randomized controlled trials (RCTs) and multicenter studies. Real-world implementation data from community clinical practice remain limited. Objective: To evaluate clinical outcomes and patient-developed self-regulation strategies of Prism neurofeedback in patients with PTSD in community clinical practice. Methods: Retrospective case series of 28 consecutive patients with PTSD treated with Prism neurofeedback in a community psychiatry practice. The primary outcome was change in PTSD Checklist for DSM-5 (PCL-5) from baseline to end of treatment. Results: Twenty-one of 28 patients (75.0%) completed treatment. Mean PCL-5 reduction was 37.0 ± 18.2 points (Cohen’s d = 2.03). Response rates were 100% for any improvement and 90.5% for clinically significant improvement (≥10-point reduction). Five patients (23.8%) achieved excellent response with ≥50-point reduction. Limited follow-up data (1–3 months post-treatment) were available for three patients; two of three (67%) exceeded their end-of-treatment gains. Four patients receiving booster sessions showed continued improvement. Limitations: The uncontrolled, retrospective design precludes causal attribution of improvements to the intervention versus placebo effects or regression to the mean. The 25% early discontinuation rate may introduce attrition bias. Durability data are available for only three patients. Conclusions: This case series provides real-world evidence supporting the feasibility and potential clinical utility of Prism neurofeedback in community practice, with outcomes comparable to controlled studies and preliminary evidence of durable treatment effects. These findings complement existing RCT evidence by demonstrating successful implementation outside research settings.

  • Open Access

    An fMRI-informed EEG model of the amygdala is associated with salience network dynamics during naturalistic emotional stimulation

    by Talia Brandman, Yaki Stern, Guy Gurevitch, Tal Harmelech, Gal Shoval, Oded Kraft, Aron Tendler, Talma Hendler

    The amygdala-derived EEG-fMRI pattern (Amyg-EFP) is an EEG model of fMRI amygdala activity with demonstrated therapeutic implications in neurofeedback interventions aimed at emotion regulation. Yet, its distributed neural correlates and potential relevance for emotional processing, independent of active modulation by neurofeedback, remain unexplored. This study aimed to characterize the distributed brain activations captured by the Amyg-EFP during passive processing of naturalistic emotional stimuli. Using simultaneous EEG-fMRI during stimulation with emotional movie and music excerpts in 71 healthy participants, we examined the spatiotemporal coupling between the Amyg-EFP and fMRI activations across the brain. We further measured the correlation of the Amyg-EFP with individual emotional reactivity ratings of the movie stimuli. Results revealed a correspondence between Amyg-EFP signal modulation and salience-network dynamics, tracking the anterior insula, dorsal anterior cingulate cortex, and salience-coactivated amygdala subregions. This association was specific to the Amyg-EFP, as a control EFP derived from the ventral striatum showed a different coupling pattern. In addition, the Amyg-EFP, but not the control EFP, was associated with emotional reactivity ratings of movie stimuli. Together, these findings tie localized amygdala activity captured by the Amyg-EFP, with broader salience-network dynamics and with individual reactivity, during the processing of emotional stimuli. Thereby, this study highlights the relevance of the Amyg-EFP for emotional reactivity, and its potential as a target in brain-based interventions for psychiatric disorders characterized by emotional dysregulation.


  • Open Access

    Amygdala-targeted neurofeedback for dissociative symptoms in PTSD: Converging evidence from three independent studies

    by Tal Harmelech, Talma Hendler, Guy Gurevitch, Naomi Fine, Eyal Fruchter, Daniela Amital, Nadav Goldental, Raz Gross, Matthew A Robinson, Lauren Am Lebois, et al.

  • Open Access

    Cost Effectiveness of Adjunctive Neurofeedback vs. Psychotherapy or Pharmacotherapy for Post-Traumatic Stress Disorder

    by Jeffrey D. Voigt, Aron Tendler, Carl Marci, Linda L. Carpenter

    Background: Neurofeedback shows promise as an adjunctive therapy for post-traumatic stress disorder (PTSD), but its cost effectiveness has not been studied. Objectives: To assess the cost and effectiveness of neurofeedback plus other therapies (NF + OT) vs. guideline therapies alone. Methods: TreeAge software was used to develop Markov models comparing NF + OT therapy to psychotherapy and pharmacotherapy over 1–3 years. Costs were derived from Medicare rates and literature. Effectiveness was measured using CAPS-5 score reductions converted to quality-adjusted life years (QALYs) using regression analysis. Dropout and relapse rates were derived from systematic reviews and meta-analysis. Results: NF + OT resulted in greater improvements in CAPS-5 scores and was less costly than OT. In the base case, NF + OT was less expensive (on average) for years 1–3 by USD 2568−USD 4140 (vs. psychotherapy) and USD 2282−USD 7217 (vs. pharmacotherapy). QALYs improved by 0.04 compared to psychotherapy and 0.24 compared to pharmacotherapy. NF + OT dominated (lower cost, better outcomes) psychotherapy 12% of the time and pharmacotherapy 26.5% of the time in Monte Carlo simulation. Further, Monte Carlo simulation did not demonstrate dominance at any point in time for either pharmacotherapy or psychotherapy over NF + OT. Conclusions: Based on lower costs and improved effectiveness, NF + OT should be considered for treating PTSD.

  • Open Access

    Safety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis

    by Yiftach Roth, Aron Tendler, Gaby S. Pell, TeeJay Tripp, Philip Yam, Dianne DeKeyser, Mah Mekolle, Jayson Tripp, Aaron J. Dahl, Owen S. Muir, et al.


  • Open Access

    Reward System EEG–fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study

    by Daniela Amital, Raz Gross, Nadav Goldental, Eyal Fruchter, Haya Yaron-Wachtel, Aron Tendler, Yaki Stern, Lisa Deutsch, Jeffrey D. Voigt, Talma Hendler, et al.

    Background/Objectives: Up to 75% of patients with major depressive disorder (MDD) exhibit persistent anhedonia symptoms related to abnormalities in the positive valence system. Cumulative evidence points to brain dysfunction in the reward system (RS), including in the ventral striatum, in patients with MDD with anhedonia. This study aims to evaluate the safety and efficacy of a novel neurofeedback (NF) device (termed Prism) which incorporates the EEG–FRI-Pattern biomarker of the reward system (RS-EFP) for use in self-neuromodulation training (RS-EFP-NF) for alleviating depression in patients with MDD with anhedonia. Methods: A total of 49 adults (age range: M = 39.9 ± 11.03) with a DSM-5 diagnosis of MDD with anhedonia (per a SHAPS-C score ≥ 25) were screened for the administration of ten sessions of RS-EFP-NF twice a week on nonconsecutive days. Depression and anhedonia severity was assessed, respectively, by HDRS-17 and SHAPS-C at baseline, midway, and treatment end. Results: A total of 34 patients (77%) completed the protocol and were included in the analyses. No device-related adverse events were serious or required treatment. Depression symptoms were reduced at end of treatment as indicated by the HDRS-17, with a reduction of eight points on average (95% CI: −10.5 to −5.41, p < 0.0001), a clinical improvement rate of 78.47%, and a remission rate of 32.25%. Anhedonia, as indicated by the SHAPS-C score, was diminished, showing an average reduction of 6.3 points (95% CI: −8.51 to −4.14, p < 0.0001). Conclusions: Self-neuromodulation using RS-EFP-NF is a promising and safe treatment for MDD with anhedonia. The intervention demonstrates substantial clinical effects on both depression and anhedonia symptoms, with high patient acceptability and retention. Prism may address a critical mechanism-driven treatment gap for anhedonia that often persists despite conventional therapies. Larger controlled implementation, efficacy, and dosing studies are warranted.


  • Open Access

    Amygdala EFP Neurofeedback Effects on PTSD Symptom Clusters and Emotional Regulation Processes

    by Nadav Goldental, Raz Gross, Daniela Amital, Eiran V. Harel, Talma Hendler, Aron Tendler, Liora Levi, Dmitri Lavro, Tal Harmelech, Shulamit Grinapol, et al.

    Background: Post-traumatic stress disorder (PTSD) manifests through distinct symptom clusters that can respond differently to treatments. Neurofeedback guided by the Amygdala-derived-EEG-fMRI-Pattern (Amyg-EFP-NF) has been utilized to train PTSD patients to regulate amygdala-related activity and decrease symptoms. Methods: We conducted a combined analysis of 128 PTSD patients from three clinical trials of Amyg-EFP-NF to evaluate effects across symptom clusters (as assessed by CAPS-5 subscales) and on emotion regulation processing (evaluated by the ERQ). Results: Amyg-EFP-NF significantly reduced severity across all PTSD symptom clusters immediately post-treatment, with improvements maintained at three-month follow-up. The arousal and reactivity cluster showed continued significant improvement during follow-up. Combined effect sizes were large (η2p = 0.23–0.35) across all symptom clusters. Regression analysis revealed that emotion regulation processes significantly explained 17% of the variance in symptom improvement during the follow-up period. Conclusions: Reduction of PTSD symptoms following Amyg-EFP-NF occurs across all symptom clusters, with emotional regulation processes potentially serving as an underlying mechanism of action. These results support Amyg-EFP-NF as a comprehensive treatment approach for PTSD that continues to show benefits after treatment completion.